#20. Bayer Corp.
Bayerwerk, Gebäude W11
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
Tel: (49) 214 30 1
Fax: (49) 214 30 66328
www.bayer.com
| Headcount* |
93,700 |
|
| Year Established |
1971 |
|
| Pharma Revenues |
$5,065 |
+3% |
| Total Revenues |
$34,103 |
+18% |
| Net Income |
$1,989 |
+133% |
| R&D Budget** |
$1,188 |
-5% |
* 16,900 in pharma/biologics
** R&D only for Bayer Healthcare unit
| Drugs Approved/Launched |
| Drug |
Indication |
| nexavar |
advanced renal cell carcinoma |
| Drugs Pending approval |
| Drug |
Indication |
| nexavar |
metastatic liver cancer |
| Drugs in Phase IIb and Beyond |
| Drug |
Indication |
| bay 59-7939 |
venous thromboembolism |
| nexavar |
advanced liver and skin cancer, non-small-cell lung cancer |
| alfi meprase |
blood clot dissolver |
| Early Research Projects |
| Drug |
Indication |
| kogenate |
new formulation |
| Top Selling Drugs |
| Drug |
Indication |
Sales |
(+/- %) |
| ascensia |
diabetes |
$701 |
12% |
| kogenate |
hemophilia |
$663 |
18% |
| adalat |
hypertension |
$659 |
-2% |
| cipro |
antibiotic |
$525 |
-37% |
| avalox |
antibiotic |
$364 |
15% |
Account for 57% of total pharma sales, down from 62% in 2004.
